



Bridging Pharmacoepidemiology and Pharmacoeconomics for Better Healthcare Outcomes

Guest Editor:

Dr. Hao Hu

Institute of Chinese Medical
Sciences, University of Macau,
Macao, China

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

The quality use of economic pharmacotherapy has always been a central topic in public health. Randomized controlled trials (RCTs) are the gold standard for drug effectiveness and safety research, whereas the characteristics of RCTs (such as a narrow group of participants, relatively short durations of therapies, and strict implementation of randomization) narrow their external validity when applying the trialed drugs in general populations with diverse characteristics and distinct utilization scenarios. Real-world evidence provides insights beyond those derived from RCTs in medical assessments and clinical practice decisions, along with innovative drug assessment approaches based on pharmacoepidemiology and pharmacoeconomics.

Authors are welcome to submit original articles and systematic reviews on the effectiveness, safety, and economic burden of pharmacotherapies based on real-world data. Studies bridging pharmacoepidemiology and pharmacoeconomics are of particular interest to this Special Issue. We look forward to receiving your contributions.

